Neuraxis (NRXS) Enterprise Value (2022 - 2026)
Neuraxis (NRXS) posted Enterprise Value of -$7.1 million for Q1 2026, down 61.72% sequentially from -$4.4 million in Q3 2025, and down 252.99% YoY from $4.6 million in Q1 2025.
Neuraxis (NRXS) Enterprise Value (2022 - 2026) Analysis & Trends
Neuraxis has reported Enterprise Value for 5 years, with the latest figure at -$7.1 million in Q1 2026.
- Quarterly Enterprise Value fell 252.99% year-over-year to -$7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.1 million (down 252.99% YoY) and the FY2023 annual result came in at -$78560.0, up 69.03% from the prior year.
- Enterprise Value declined to -$7.1 million in Q1 2026 per NRXS's latest filing, from -$4.4 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$51440.0 in Q2 2023 and troughed at -$7.1 million in Q1 2026.
- A 5-year average of -$2.1 million and a median of -$761249.0 in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value jumped 69.03% in 2023, then slumped 3331.71% in 2024.
- Over 5 years, Enterprise Value stood at -$253699.0 in 2022, then surged by 69.03% to -$78560.0 in 2023, then tumbled by 232.08% to -$260885.0 in 2024, then tumbled by 1577.79% to -$4.4 million in 2025, then sank by 61.72% to -$7.1 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$7.1 million, -$4.4 million, and -$6.0 million for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Neuraxis | 75.51 Mn | 67.18 Mn | - | -8.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.32 Mn |
| Mar 31, 2026 | -7.08 Mn |
| Sep 30, 2025 | -4.38 Mn |
| Jun 30, 2025 | -5.99 Mn |
| Mar 31, 2025 | -2.01 Mn |
| Sep 30, 2024 | -260,885.00 |
| Jun 30, 2024 | -1.77 Mn |
| Mar 31, 2024 | -81,752.00 |
| Dec 31, 2023 | -78,560.00 |
| Sep 30, 2023 | -761,249.00 |
| Jun 30, 2023 | -51,440.00 |
| Dec 31, 2022 | -253,699.00 |